News
The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...
NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...
14h
InvestorsHub on MSNNektar Therapeutics Shares Surge 140% After Atopic Dermatitis Drug Meets Key Study GoalsNektar Therapeutics (NASDAQ:NKTR) saw its stock soar 140% following promising Phase 2b trial results for its experimental treatment rezpegaldesleukin in moderate-to-severe atopic dermatitis. The ...
Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...
USA: Researchers have discovered in a new study that young children with moderate-to-severe atopic dermatitis (AD) tend to be ...
This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...
Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock surged 20% following the company’s announcement that it will present top-line data from its REZOLVE-AD Phase 2b clinical trial for atopic ...
Tacrolimus has previously shown antipruritic action in atopic dermatitis, so researchers decided to investigate it for uremic pruritus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results